Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease
NCT01293604
Soybean Based Diets and CVD Risk Factors
NCT00175097
Meta-analysis of 46 FDA Identified Studies on Lipid Markers
NCT03468127
Acute Heart Health Benefits of Whole Grain Barley and Oats in Healthy Men and Women
NCT01283672
SRMA of the Effect of Soy Protein on Blood Pressure
NCT05638061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diets: The diets will be the subjects' usual diets which appropriately will be NCEP Step 2 diets for patients treated without medications with this degree of hyperlipidemia. Those who are not on an NCEP Step 2 diet will be instructed accordingly. During the first phase, the two one-week recorded diets for each patient will be photocopied and returned to the patient to be used as the dietary model for the subsequent period. We have found that this approach is effective in stabilizing the diets in our soy protein studies. Supplements: Will be breads with test and control supplements providing the identical daily energy intake. The increase in protein in the barley supplements will be matched by the use of protein from milk protein (casein). Similarly the increased polyunsaturated, monounsaturated and saturated fatty acids in the test supplement will be matched by addition of an appropriate blend of oils in the control. Baked goods will be prepared at our clinic and a seven-day supply will be provided to each participant at the beginning of each week. The exact formulation of the supplements will involve product development, palatability testing and chemical analysis of the prototypes in the initial phase of the study. Compliance: compliance will be assessed from completed weekly diet records where supplement intake is recorded daily. These records will be reviewed by a dietitian with the subject at the end of the week. In addition, uneaten supplements will be returned, weighed and noted on the menu plans by the dietitian. Diet records will also be assessed to ensure the predetermined diet plan is followed according to the phase one recorded diet.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Barley protein bread or control (casein) bread
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index \>18 kg/m2 and \< 36 kg/m2.
* treated by diet
* Alcohol intake \< 14 drinks per week.
* Fasting plasma triglyceride (TG) concentration \> 0.5 mmol/l and \< 4.5 mmol/l.
* Fasting plasma LDL cholesterol concentration \> 3.5 mmol/l at diagnosis.
Exclusion Criteria
* Taking cholesterol lowering medications at the start of the study, unless their LDL-cholesterol levels are \>3.5 mmol/L.However, with their physician's approval those who wish to join but are already taking cholesterol lowering medications with low LDL-cholesterol levels (e.g. \<2.5 mmol/L) may join the study providing the medications are stopped for one month.
* Change the type or dose of their drug treatment during the study
* Patients judged as having a likelihood of being non-compliant with instructions for whatever reason
* Food allergies
* Evidence or history of diabetes, renal liver disease or gastrointestinal disease
* Recent (within 6 months)) major cardiovascular event (stroke or myocardial infarction)
* Secondary causes of hypercholesterolemia (or untreated hypothyroidism)
* Uncontrolled blood pressure
* Major disability or disorder such as liver disease, renal failure or cancer or with major surgery \< 6 months prior to randomization
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Toronto
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David JA Jenkins, MD
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Michael's Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jenkins DJ, Srichaikul K, Wong JM, Kendall CW, Bashyam B, Vidgen E, Lamarche B, Rao AV, Jones PJ, Josse RG, Jackson CJ, Ng V, Leong T, Leiter LA. Supplemental barley protein and casein similarly affect serum lipids in hypercholesterolemic women and men. J Nutr. 2010 Sep;140(9):1633-7. doi: 10.3945/jn.110.123224. Epub 2010 Jul 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB 02-113C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.